Welcome to our dedicated page for ILLUMINA SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Illumina, Inc. reported completion of a public debt offering of $300,000,000 aggregate principal amount of 4.950% notes due 2029. The notes were issued under an existing Indenture with U.S. Bank Trust Company, National Association, and were registered on a Form S-3 shelf registration.
Illumina expects to use the net proceeds from this offering, together with cash on hand, to repay its 4.650% notes due September 9, 2026, of which $500 million aggregate principal amount was outstanding as of June 28, 2026. The new notes accrue interest at 4.950% per annum, payable semi-annually, and mature on September 19, 2029. The company may redeem the notes, in whole or in part, at specified redemption prices and on terms set forth in the note documentation, and the notes may be accelerated upon an Event of Default as defined in the Indenture.
Illumina, Inc. entered into a new $1,000 million senior unsecured revolving credit facility with a syndicate of lenders and Bank of America, N.A. as administrative agent, issuing bank and swingline lender. The facility includes a $50 million swingline sublimit and a $75 million letter of credit sublimit.
Borrowings will bear a variable interest rate based on term SOFR or an alternate base rate, plus a margin that varies with Illumina’s debt rating. The agreement permits Illumina, subject to lender consent and conditions, to increase commitments or add term loans by up to $500 million. The facility matures on August 13, 2031 and may be extended for up to three additional one-year periods. It contains a maximum total leverage ratio covenant and operating covenants limiting subsidiary indebtedness, liens, fundamental changes and asset dispositions. Amounts may be prepaid and commitments terminated at any time without premium or penalty, and there were no borrowings outstanding as of the date referenced. This facility replaces and terminates the company’s prior 2023 credit agreement.
Illumina, Inc. is offering $300,000,000 aggregate principal amount of 4.950% Notes due 2029. The senior unsecured Notes pay interest semiannually on March 19 and September 19, beginning March 19, 2027, and mature on September 19, 2029. They will be issued in minimum denominations of $2,000 and will not be listed on any securities exchange.
Illumina expects net proceeds of about $297 million, to be used with cash on hand to repay its $500.0 million 4.650% notes due September 9, 2026. As of June 28, 2026, Illumina had $2.0 billion of total debt, including four other $500.0 million note issues, and no secured debt outstanding.
The Notes are senior unsecured obligations ranking equally with Illumina’s other unsecured senior debt and structurally subordinated to obligations of its subsidiaries, which had about $831 million of liabilities as of June 28, 2026. Illumina may redeem the Notes at its option (including a par call from August 19, 2029), and must offer to repurchase them at 101% plus accrued interest upon a Change of Control Triggering Event.
Illumina, Inc. entered into an underwriting agreement to issue and sell $300,000,000 aggregate principal amount of its 4.950% notes due 2029. The transaction is with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., acting as representatives of the underwriters, and is expected to close on August 17, 2026, subject to customary closing conditions.
Illumina expects to use the net proceeds from these notes, together with cash on hand, to repay its 4.650% notes due September 9, 2026. The new notes will be issued under an effective shelf Registration Statement on Form S-3 (No. 333-281921). The detailed underwriting agreement is included as an exhibit and incorporated by reference.
ILLUMINA, INC. filed an initial insider ownership report for Julie Ann Coletti, who serves as Chief Legal Officer. The filing lists her as an officer but does not disclose any reportable transactions or equity holdings, serving solely to establish her status as a reporting person.
Illumina, Inc. plans a new offering of senior unsecured Notes under its automatic shelf registration, with specific maturity and coupon to be set at pricing. The Notes will be unsubordinated obligations, ranking equally with Illumina’s existing unsecured notes and effectively junior to any secured debt and to all liabilities of subsidiaries.
The company discloses existing indebtedness of $2.0 billion as of June 28, 2026 and subsidiary liabilities of $831 million. The Notes are callable at Illumina’s option, and upon a Change of Control Triggering Event holders may require repurchase at 101% of principal plus accrued interest. Illumina expects to use net proceeds for general corporate purposes, including repaying its 4.650% notes due September 9, 2026, of which $500.0 million was outstanding as of June 28, 2026. The Notes will be issued in minimum denominations of $2,000, in book-entry form through DTC, with no sinking fund and no planned exchange listing.
Sullivan Michael C reported acquisition or exercise transactions in this Form 4 filing.
Illumina, Inc. granted Chief Commercial Officer Michael C. Sullivan equity awards on August 5, 2026. These included 4,503 restricted stock units of common stock at $199.87 per share, vesting 25% on each of the first four anniversaries of grant. He also received two performance stock unit awards of 5,254 units each, settling in common shares on December 31, 2028 based on three-year non-GAAP EPS growth and relative total shareholder return, with actual payout ranging from 0% to 250% of target, subject to continued service.
Illumina, Inc. describes a proposed resolution of Delaware litigation brought by Icahn Partners LP and related plaintiffs challenging the company’s approximately $8 billion acquisition of GRAIL, Inc. Illumina and current and former directors entered a Release Agreement on August 21, 2025, providing mutual releases with no payments by any party.
Under the agreement, the action Icahn Partners LP v. deSouza will be dismissed with prejudice as to those plaintiffs only and without prejudice to all other Illumina stockholders, including plaintiffs in three separate derivative actions that remain pending. The Delaware Court of Chancery will hold a hearing on the proposed dismissal on November 2, 2026, at 1:30 p.m. Eastern time. Stockholders of record on April 3, 2023 and current stockholders as of July 31, 2026 receive notice and may object under specified procedures. Defendants continue to deny the plaintiffs’ claims, and the court has made no findings on the merits.
Illumina, Inc. director Keith A. Meister reported that private investment funds for which Corvex Management LP acts as investment adviser sold 741,127 shares of Illumina common stock on August 4–5, 2026, in multiple transactions described as open‑market or private sales at weighted‑average prices between $196.74 and $203.28 per share. The securities are held for Corvex‑advised funds’ accounts, and both Corvex and Meister disclaim beneficial ownership beyond their pecuniary interests. A footnote corrects earlier Section 16 reports, stating the funds indirectly owned 2,830,552 shares before these sales, while Meister continues to hold 6,780 shares directly.
Illumina, Inc. (ILMN) has a planned sale of Common Stock under Rule 144. The notice covers up to 840,000 shares of common stock, par value $0.01 per share, to be sold through Goldman Sachs & Co. LLC on the Nasdaq Global Select Market, with an aggregate market value of $166,454,400 as of August 4, 2026.
The filing also lists prior sales by Corvex Management LP over the past three months, including 225,067 shares for $32,760,165.38 on May 13, 2026 and several additional sales in May and June 2026.